基本信息
浏览量:0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Clinical Trials and Research Studies
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
AALL1631: International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
研究兴趣
论文共 201 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
NEURO-ONCOLOGYno. Supplement_2 (2024): S155-S164
NEURO-ONCOLOGY PRACTICEno. 2 (2024): 188-198
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 13 (2024): 1542-1552
Journal of Clinical Oncologyno. 16_suppl (2024): 2088-2088
Blood advances (2023)
NEURO-ONCOLOGY ADVANCESno. 1 (2023)
crossref(2023)
Neuro-oncology advancesno. 1 (2023)
PEDIATRIC BLOOD & CANCER (2023): S181-S182
引用0浏览0引用
0
0
加载更多
作者统计
#Papers: 201
#Citation: 3664
H-Index: 34
G-Index: 59
Sociability: 7
Diversity: 2
Activity: 41
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn